Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 12, 2015 at 8:30 a.m. Pacific Time/11:30 a.m. Eastern Time.
Help employers find you! Check out all the jobs and post your resume.
